Charting the Chemical Space of Acrylamide-Based Inhibitors of zDHHC20

• Published in: ACS medicinal chemistry letters Vol. 13; no. 10; pp. 1648 - 1654
• Main Authors: Azizi, Saara-Anne, Delalande, Clémence, Lan, Tong, Qiu, Tian, Dickinson, Bryan C.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 13-10-2022
• Subjects: Letter; DHHC family; covalent inhibitors; structure−activity relationship; Protein S-acylation
• ISSN: 1948-5875; 1948-5875
• DOI: 10.1021/acsmedchemlett.2c00336

Protein S-acylation is a dynamic and reversible lipid post-translational modification that can affect the activity, stability, localization, and interactions of target proteins. Lipid modification occurs on cysteine residues via a thioester bond and in humans is mediated by 23 Asp-His-His-Cys domain-containing protein acyltransferases (DHHC-PATs). The DHHC-PATs have well-known roles in physiology and disease, but much remains to be discovered about their biological function and therapeutic potential. We recently developed cyanomyracrylamide (CMA), an acrylamide-based DHHC inhibitor with key improvements over existing inhibitors. Here we conduct a structure–activity relationship (SAR) study of CMA and its acrylamide derivatives against zDHHC20, the most structurally characterized member of the human DHHC family, and validate the results against the homologous zDHHC2. This SAR maps out the limitations and potential of the acrylamide scaffold, underscoring the need for a bivalent inhibitor and identifying along the way three molecules with activity on par with CMA but with an improved logP.